project koenig

Download Project Koenig

Post on 30-Dec-2015

12 views

Category:

Documents

1 download

Embed Size (px)

DESCRIPTION

Information Memorandum June 2012. Project Koenig. Transaction Summary. Genesis of Project Koeing US: The Backdrop. The Backdrop. Company’s Formation. - PowerPoint PPT Presentation

TRANSCRIPT

  • Information MemorandumJune 2012Project Koenig

    *

    Transaction Summary

    Company NameProject KoeingYear of Incorporation2003 in the US and 2005 in IndiaNature of BusinessMedical Device and BiotechnologyPromotersProject Koeing US

    RequirementsThe Promoters are looking for private equity funding round of US$ 30 mn / Outright sale

    *

    Genesis of Project Koeing US: The Backdrop The BackdropOver last few decades, global Pharma companies experience rising competition and costs related to conducting research on patented molecules. Thus, they increasingly resort to outsourcing this research or acquiring commercially attractive and ready molecules, esp. Biotech product patentsDuring the last over 8-10 years, the price of biotech molecules grew substantially ranging between US$ 0.5-16.0 bn. and several large transactions took place with Pharma companies buying or licensing out these molecules from biotech companiesHowever, the scientists responsible for developing these molecules were rarely sufficiently compensated, leading to a significant level of frustration in the scientist community, On the other hand, the biotech companies walked away with huge profitsAlso, while the society was benefited with new innovative products, they came at a high costCompanys FormationGiven his extensive experience in the Pharma and medical field, the key promoter of Project Koeing US (PK US), identified a unique opportunity of creating a platform for research scientists wherein they could internally develop patented molecules at effective costs and reap financial rewards for their effortsWith this background, PK US was formed in year 2003Many well renowned scientists from the U.S. and India joined PK US as equity holders in the Company and are currently on the Scientific Advisory Board, guiding the development of molecules they have themselves developedThe Companys entire research team is not only fully dedicated to serving the society with their research contributions but is also focused on providing the same at more economical rates that would not have been possible otherwise

    *

    Project Koeing: A Snapshot

    *

    The Company Structure Sub 1 The Company has been created for the commercialisation of Manufacturing technology platform for manufacture of recombinant protein

    Sub 3 The Company has been created for the commercialisation of A Immune system boosting cytokine technology for breast cancer Products Sub 2 The Company has been created for the commercialisation of a novel platform based on nucleic acid technology. The 1st product has already been shown to be safe and efficacious in cancer in Phase II human clinical trials and is all set for Phase3 studies with all approvals in placeProject Koeing Sub 4Malaysia This division would undertake development of Biotechnology and Medical device projects In Malaysia Currently a CAD Based Breast Cancer detection Project has been developed and is ready to market

    100% equity100% equity100% equity30% equity

    *

    In-house Value Add during the Development ProcessLicensing out/Sale of the Developed MoleculesIn-licensing of Molecules/Technology PlatformsTypical Timeline 3/4 YearsProject Koeing India licenses out new molecules or a technology platform from Pharma companies and takes over the remaining development process. The original creator (scientist) of the molecule typically takes an equity stake in Project Koeing IndiaProject Koeing India manages the entire development cycle of the molecule/platform in a more efficient & cost effective mannerThe Company aims to:Create cheaper and effective drugs to fight cancer. The Company is able to significant reduce the development costs of molecules as compared to Pharma Generic companiesQuick turnaround of the processThe Company enjoys the unique advantage of having various renowned scientists besides the original creator of the molecule/technology that provide extremely valuable insights during the development processes of these molecules/platformsOnce the development process is complete, Project Koeing India plans to license out or sell the developed molecules to global Pharma company that will launch these drugs into the marketIncase of licensing out, Project Koeing India will continue to hold all the patents related to the molecules/technologies, which can be further used to develop new technologies in related areasThe upfront payment received from the Pharma companies and the periodic royalties etc will be main revenue generators, which will be shared with the original creators of molecules/technologiesProject Koeing India: A Unique Business ModelVarious Stages

    *

    The Technology Platform PKI various projects such as these have strong technological validates from institutions including US FDA, DCGI (India), Dept. of Science & Technology (Govt. of India), Malaysian Biotechnology Corp. etcPut together, these molecules have a market potential of over US$ 50 Bn.; PKI first exit of a Molecule/Platform is expected to take place in the next 18-24 months; Prospective collaborators for these technologies include Merck, Roche, GSK, Pfizer etcProject Koeing is consistently working on creating its future pipeline of molecules/platforms etc and currently is in process of acquiring/licensing another 5-7 technologies

    *

    Five Key Projects in the Pipeline RNAi 12 to 18 monthsA Phase III-stage clinical candidate that belongs to a novel class of molecules called ribozymes, which work by destroying mRNA molecules of target proteins; This is for the treatment of colorectal cancerManufacturing Tech. 6 months A platform technology for bio-manufacturing of recombinant proteins in yeast-based expression systemsAffinity based drug delivery 24 to 36 monthsAn early clinical stage candidate that belongs to a novel class of molecules that work by organ targeted drug delivery; This is for the treatment of liver cancerImmuno-therapy 60 monthsAn early-stage program to discover and develop a Immuno Therapy based cytokine which will be able to help boost the immune response to fight against melanoma, Lymphoma and Rena cell carcinoma etc.Key Projects in the PipelineCAD Tech 3 MonthsA Medical Device platform technology for not only detection of various types of abnormalities like cancer but also automated Biopsy and drug delivery

    *

    Enhanced Protein Expression Technology Manufacturing Tech.This is an interesting technology to increase the yield of fermented products and the yield is as much as 5-10 times more in fermentation of recombinant proteins, leading to substantial decrease in production cost

    *

    RNAiThe DCGI has approved it for Phase III clinical trials in India at 20 cancer centers. RNAi based products will most likely be the first product to hit the market in the next 18-24 months with a high success rate and huge market potential

    *

    Affinity based Drug deliveryLIV1 is an early clinical stage candidate that belongs to a novel class of molecules that work by organ targeted drug delivery and is targeted at treating Liver related cancers

    *

    Immuno TherapyCytokine Technology is an early clinical stage gene therapy product that is targeted at treating Renal Cell Carcinoma, Myloma/ Lymphoma and other kinds of cancer

    *

    CAD TechnologySpacer for InhalationCADReady for Market todayProject Koeing has acquired an interesting technology for use in various asthmatic conditions. where the new spacers patented, developed, approved by US FDA can be of tremendous use in delivering much higher quantity of drug into the lungs as compared to the current traditional inhalers The CAD based technology for diagnosis of breast cancer and other types soft tissue of cancers. It is a validated technology in the sense that the company has already received Bionexus status from the Malaysian Biotechnology Corporation Sdn. Bhd. The Company in Malaysia will go into production as soon as funding can be obtained. In Studies involving over 400 patients the technology has shown to have an accuracy of 95% with less than 1 false positive in 4 films.

    *

    The Promoter TeamCo FounderFounderHas spent over 40 years in the pharmaceutical industryCommenced at age 19 in Schering AG; Grew up to the level of All India No. 2, at the age of 27Joined The UB Group as General Manager [Corporate Management div.]; Grew to the level of President Life Science Division, and was running 7 group companies in India and AfricaWas a member of Hoechst AgrEvo board, Aventis AgrEvo, and several other UB Group companiesWas responsible for bringing pain killer Combiflamin India, and several other successful brands of the groupPresident Project Koeing India for last four years. Also Director, of a leading Neutraceutical company.Graduate in Engineering from the USOver 23 years of experience in Biotechnology- both in the US & IndiaFounder and Executive Vice President of a CMO [worked in using Mammalian and Yeast Cell lines]. Subsequently, founded a BioInstruments company [Nasdaq quoted company], which was involved in the marketing of sophisticated equipments for Biotech R&D. Prior to this he was associated with a Medical device company- a CAD based diagnostic Tech companyFounder, Managing Director of PK US and its associate companies in India and Malaysia

    *

    Senior Management Team

    ManagementQualifications & ExperienceDirector Medical Affairs, Project Koeing IndiaWas Director Medical Affairs, Hoechst, Aventis; Later, Vice President at Zydus Cadila Incharge Regulatory AffairsWas previously working with Bharat BiotechHead, R&DWas professor in Texas Health centre. Director for Gene Transfer Technologies for Cancer Therapy & Research Center, Texas [USA] and was the Head-Biology Research for Reliance Life Sciences [Mumbai; Ph.D with Molecular Virology & Oncology, Wisconsin, U.S.Executive Vice President Legal and Com